Clinical Trial Update: The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and tolerability of COMP360 in adults with post-traumatic stress disorder has completed, with results posted on 2025-06-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• COMP360 (psilocybin)

Snippet

Sponsor: COMPASS Pathways | Conditions: Post Traumatic Stress Disorder | Phase 2 | Status: COMPLETED | Results posted: 2025-06-13